BRIDGEBIO PHARMA
BridgeBio is a biotechnology company that focuses on genetic disease therapies and develops those assets with the right approach in supporting R&D. BridgeBio creates a bridge from advancements in genetic science to patients with unmet needs via the entrepreneurial engine required to make life-changing medicines as rapidly as possible. BridgeBio's mission is to discover, create, test, and deliver transformative medicines to treat patients with genetic diseases.
BRIDGEBIO PHARMA
Industry:
Biotechnology Health Care Life Science Medical Pharmaceutical
Founded:
2014-01-01
Address:
Palo Alto, California, United States
Country:
United States
Website Url:
http://www.bridgebio.com
Total Employee:
251+
Status:
Active
Contact:
650-391-9740
Email Addresses:
[email protected]
Total Funding:
1.95 B USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Font API LetsEncrypt Google Tag Manager WordPress Domain Not Resolving Apache
Current Advisors List
Current Employees Featured
Founder
Stock Details
Acquisitions List
| Date | Company | Article | Price |
|---|---|---|---|
| 2020-10-05 | Eidos Therapeutics | Eidos Therapeutics acquired by BridgeBio Pharma | 175 M USD |
Investors List
Perceptive Advisors
Perceptive Advisors investment in Series D - BridgeBio Pharma
Sequoia Capital
Sequoia Capital investment in Series D - BridgeBio Pharma
AIG Investments
AIG Investments investment in Series D - BridgeBio Pharma
Cormorant Capital
Cormorant Capital investment in Series D - BridgeBio Pharma
Aisling Capital
Aisling Capital investment in Series D - BridgeBio Pharma
Viking Global Investors
Viking Global Investors investment in Series D - BridgeBio Pharma
Hercules Capital
Hercules Capital investment in Series D - BridgeBio Pharma
Kohlberg Kravis Roberts
Kohlberg Kravis Roberts investment in Series D - BridgeBio Pharma
Janus Fund
Janus Fund investment in Series C - BridgeBio Pharma
Perceptive Advisors
Perceptive Advisors investment in Series C - BridgeBio Pharma
Investments List
| Date | Company | Article | Money raised |
|---|---|---|---|
| 2018-04-05 | Eidos Therapeutics | BridgeBio Pharma investment in Series B - Eidos Therapeutics | 64 M USD |
| 2018-01-30 | QED Therapeutics | BridgeBio Pharma investment in Venture Round - QED Therapeutics | 65 M USD |
| 2017-08-01 | PellePharm | BridgeBio Pharma investment in Series B - PellePharm | 20 M USD |
| 2015-04-30 | MyoKardia | BridgeBio Pharma investment in Series B - MyoKardia | 46 M USD |
| 2014-08-22 | MyoKardia | BridgeBio Pharma investment in Venture Round - MyoKardia | 10 M USD |
Official Site Inspections
http://www.bridgebio.com Semrush global rank: 2.1 M Semrush visits lastest month: 9.77 K
- Host name: 141.193.213.21
- IP address: 141.193.213.21
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
More informations about "BridgeBio Pharma"
BridgeBio | Biotechnology Company | Designing Transformative …
BridgeBio is a biotechnology company designing transformative medicines for patients with genetic diseases and cancers with clear genetic drivers.See details»
BridgeBio - Crunchbase Company Profile & Funding
BridgeBio is a biotechnology company that focuses on genetic disease therapies and develops those assets with the right approach in supporting R&D. …See details»
BridgeBio | For Investors
The Investor Relations website contains information about BridgeBio Pharma's business for stockholders, potential investors, and financial analysts.See details»
BridgeBio - The Org
BridgeBio finds, develops, and delivers breakthrough medicines for genetic diseases.See details»
BridgeBio Pharma, Inc. - AnnualReports.com
BridgeBio is a team of experienced drug discoverers, developers and innovators working to create life-altering medicines that target well-characterized genetic diseases at their source. BridgeBio was founded in 2015 to identify and …See details»
Hub-and-Spoke Biotechs: BridgeBio - by …
Feb 16, 2025 More specifically, a holding company that owned and operated a portfolio of biotech firms making medicines for specific genetic diseases. Adapted from the BridgeBio S-1. In …See details»
BridgeBio Pharma
3 days ago BridgeBio was founded in 2015 by Neil Kumar and Nishanth Allegatu. The company initially focused on genetic disease research and has spun out more than 20 companies in the five years since its formation. BridgeBio’s portfolio companies are developing treatments for an …See details»
BridgeBio Oncology Therapeutics - Crunchbase
May 2, 2024 Where is BridgeBio Oncology Therapeutics's headquarters? BridgeBio Oncology Therapeutics is located in Palo Alto, California, United States. Who invested in BridgeBio Oncology Therapeutics? BridgeBio …See details»
BridgeBio | BridgeBio Reports First Quarter 2025 Financial Results …
Apr 29, 2025 About BridgeBio Pharma, Inc. BridgeBio Pharma, Inc. (BridgeBio) is a new type of biopharmaceutical company founded to discover, create, test, and deliver transformative medicines to treat patients who suffer from genetic diseases. BridgeBio’s pipeline of …See details»
BridgeBio Pharma Inc: Overview - GlobalData
BridgeBio Pharma Inc (BridgeBio) is a commercial-stage biopharmaceutical company that primarily focuses on the discovery, creation, testing, and delivery of transformative medicines.See details»
Hassan, Ellis and Dachille Join Board of Directors | BridgeBio
Aug 18, 2021 BridgeBio’s pipeline of over 30 development programs ranges from early science to advanced clinical trials and its commercial organization is focused on delivering the company’s two approved therapies.See details»
BridgeBio | BridgeBio Pharma, Inc. and Oregon Health & Science ...
Apr 13, 2021 BridgeBio’s pipeline of over 30 development programs ranges from early science to advanced clinical trials and its commercial organization is focused on delivering the company’s first approved therapy.See details»
BridgeBio Company Profile - Office Locations, Competitors ... - Craft
BridgeBio has 2 employees at their 1 location and $221.9 m in annual revenue in FY 2024. See insights on BridgeBio including office locations, competitors, revenue, financials, executives, subsidiaries and more at Craft.See details»
BridgeBio Announces Commercial Progress, Program Updates
Jan 14, 2025 BridgeBio Pharma, Inc. (BridgeBio) is a new type of biopharmaceutical company founded to discover, create, test, and deliver transformative medicines to treat patients who suffer from genetic diseases.See details»
BridgeBio | BridgeBio Receives FDA’s Regenerative Medicine …
Sep 10, 2024 BridgeBio’s pipeline of development programs ranges from early science to advanced clinical trials. BridgeBio was founded in 2015 and its team of experienced drug discoverers, developers and innovators are committed to applying advances in genetic …See details»
Mission, Vision & Core Values of BridgeBio
Dec 19, 2024 BridgeBio Mission, Vision & Core Values: BridgeBio is dedicated to advancing a diverse portfolio of innovative medicines to address the unmet medical needs of patients with genetic diseases. With a vision to transform the lives of patients and their families through …See details»
BridgeBio and Bristol Enter License Agreement | BridgeBio
May 12, 2022 BridgeBio announced an exclusive license with Bristol Myers Squibb to develop and commercialize BBP-398 in oncology.See details»
Why BridgeBio Pharma, Inc. (BBIO) Surged on Wednesday
6 days ago Shares of BridgeBio Pharma, Inc. (NASDAQ:BBIO) rallied by 5.33 percent on Wednesday to finish at $38.36 each as investors cheered the company’s sales from its new heart drug, beating analyst ...See details»
Form 10-K for Bridgebio Pharma INC filed 02/22/2024
BridgeBio Pharma, Inc. (Exact name of registrant as specified in its charter) Delaware State or other jurisdiction of incorporation or organization 84-1850815 (I.R.S. Employer Identification No.) 3160 Porter Drive, Suite 250, Palo Alto, CASee details»
BridgeBio Reports First Quarter 2025 Financial Results
Apr 29, 2025 BridgeBio Pharma, Inc. (BridgeBio) is a new type of biopharmaceutical company founded to discover, create, test, and deliver transformative medicines to treat patients who suffer from genetic ...See details»